Next Article in Journal
Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
Previous Article in Journal
Perspective: Cellular and Molecular Profiling Technologies in Personalized Oncology
Open AccessArticle

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail

1
Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland
2
Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2019, 9(4), 45; https://doi.org/10.3390/jpm9040045
Received: 19 July 2019 / Revised: 4 September 2019 / Accepted: 12 September 2019 / Published: 2 October 2019
Drug metabolic enzymes and transporters are responsible for an important variability in drug disposition. The cocktail approach is a sound strategy for the simultaneous evaluation of several enzyme and transporter activities for a personalized dosage of medications. Recently, we have demonstrated the reliability of the Geneva cocktail, combining the use of dried blood spots (DBS) and reduced dose of phenotyping drugs for the evaluation of the activity of six cytochromes and P-glycoprotein (P-gp). As part of a study evaluating potential drug–drug interactions between probe drugs of the Geneva cocktail, the present paper focuses on the impact of cytochromes (CYP) probe drugs on the disposition of fexofenadine, a P-gp test drug. In a randomized four-way Latin-square crossover study, 30 healthy volunteers (15 men and 15 women) received caffeine 50 mg, bupropion 20 mg, flurbiprofen 10 mg, omeprazole 10 mg, dextromethorphan 10 mg, midazolam 1 mg, and fexofenadine 25 mg alone (or as part of a previously validated combination) and all together (Geneva cocktail). The determination of drug concentrations was performed in DBS samples and pharmacokinetic parameters were calculated. Fexofenadine AUC0–8 h and Cmax decreased by 43% (geometric mean ratio: 0.57; CI 90: 0.50–0.65; p < 0.001) and 49% (geometric mean ratio: 0.51; CI 90: 0.44–0.59; p < 0.001), respectively, when fexofenadine was administered as part of the Geneva cocktail in comparison to fexofenadine alone. Consequently, the apparent oral clearance (Cl/F) increased 1.7-fold (CI 90: 1.49–1.93; p < 0.001). There was no interaction between the remaining probes. In conclusion, an unexpected interaction occurred between fexofenadine and one or several of the following substances: caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan, and midazolam. Further studies are necessary to elucidate the mechanism of this interaction. View Full-Text
Keywords: precision medicine; P-glycoprotein; phenotyping; cocktail precision medicine; P-glycoprotein; phenotyping; cocktail
Show Figures

Figure 1

MDPI and ACS Style

Bosilkovska, M.; Magliocco, G.; Desmeules, J.; Samer, C.; Daali, Y. Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail. J. Pers. Med. 2019, 9, 45.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop